Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB), a leader in high-quality sequencing solutions, will participate in Cowen's 43rd Annual Health Care Conference on March 7, 2023, at 12:50 PM ET. The event will feature a fireside chat with company management, available via a live and archived webcast on the investor page at pacb.com. PacBio is focused on addressing complex genetic challenges through advanced sequencing technologies, including HiFi long read and SBB short read sequencing. The company's solutions are applicable across various research domains, such as human germline sequencing, oncology, and infectious disease.
PacBio (NASDAQ: PACB) reported its Q4 and fiscal year 2022 financial results, revealing a 24% revenue decline to $27.4 million compared to $36.0 million in the previous year. Instrument revenue fell to $6.1 million, while consumables revenue increased to $16.7 million. The company recorded a net loss of $84.4 million in Q4, worsening from a loss of $69.3 million in Q4 2021, leading to a net loss per share of $0.37. For the fiscal year, total revenue of $128.3 million was down 2% from 2021, with a net loss of $314.2 million, up from $181.2 million the prior year. Despite challenges, PacBio noted increased orders for its Revio systems and a robust cash position of $772.3 million.
On February 7, 2023, PacBio (NASDAQ: PACB) announced plans to enhance its Multiplexed Arrays Sequencing (MAS-Seq) technology for new assays on the Sequel II/IIe and Revio systems. This initiative follows the successful introduction of MAS-Seq, which significantly increases throughput for single-cell isoform sequencing by up to 16-fold. The company aims to expand applications to bulk RNA sequencing and 16S rRNA studies, offering cost-effective solutions and comprehensive software. PacBio anticipates launching the first expanded MAS-Seq kits in the second half of 2023, addressing customer demand for full-length RNA sequencing.
PacBio (NASDAQ: PACB) announced it will hold a conference call on February 16, 2023, at 4:30 PM ET to discuss its fourth quarter and full year 2022 financial results. The call will be accessible via webcast on the company's investor relations website. PacBio is known for developing advanced sequencing solutions aimed at resolving complex genetic problems, utilizing its HiFi long read and emerging SBB® short read sequencing technologies for various research applications, including oncology and infectious diseases.
Pacific Biosciences of California (PACB) announced the pricing of its public offering of 17,500,000 shares at $10.00 each, aiming to raise approximately $175 million. The underwriters, including Goldman Sachs and Morgan Stanley, have a 30-day option for an additional 2,625,000 shares. The proceeds will be utilized for research and development, expanding commercial infrastructure, and general corporate purposes. The offering is set to close on January 27, 2023, pending customary conditions.
Pacific Biosciences of California (NASDAQ: PACB) plans to offer $150.0 million in common stock through an underwritten public offering, with an additional $22.5 million option for underwriters. Proceeds will support research and development, expand commercial infrastructure, and cover general corporate expenses. The offering is subject to market conditions and is filed under a shelf registration statement with the SEC. Notably, there are no current commitments for additional acquisitions despite the potential for investing in complementary businesses and technologies.
Summary not available.
PacBio announced strong demand for its Revio system, with orders for 76 units in Q4 2022, marking a record for the company. Despite this, the preliminary revenue for the quarter is expected to be approximately $27.3 million, a 24% decline from Q4 2021. The full year 2022 revenues are projected at $128.2 million, down 2%. The company also reported significant growth in consumable sales with $59.9 million expected. The Revio system allows for up to 1,300 human genomes to be sequenced annually at low costs, while the Onso system is in beta testing with promising feedback.
PacBio (NASDAQ: PACB) has partnered with the University of Tokyo, Graduate School of Medicine, to explore the application of long-read sequencing and bioinformatics techniques aimed at identifying the genetic roots of rare diseases in the Japanese population. This collaboration will enhance the understanding of complex genetic regions and variants, benefiting ongoing research in Japan. Notably, PacBio's software tools like the Tandem Repeat Genotyping Tool will aid researchers in uncovering disease-associated variants, particularly structural variants.
PacBio (NASDAQ: PACB) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The company will host a panel discussion on January 10, 2023, at 5:15 PM PT, focused on Multiomics. Additionally, a company presentation and Q&A session will take place on January 11, 2023, at 1:30 PM PT. Live webcasts will be available on PacBio's investors page, with replays accessible for 30 days post-event. PacBio specializes in advanced sequencing solutions aimed at resolving complex genetic problems.